Study of CB-839 in Combination w/ Paclitaxel in Participants of African Ancestry and Non-African Ancestry With Advanced Triple Negative Breast Cancer (TNBC)
Completed · Phase 2
Conditions studied: Triple Negative Breast Cancer, TNBC - Triple-Negative Breast Cancer
In brief
CX-839-007 is an open-label Phase 2 study of the combination of CB-839 with paclitaxel in participants of African ancestry and non-African ancestry with advanced triple negative breast cancer. Multiple single-arm cohorts will be enrolled in which 800 mg twice daily (BID) CB-839 will be administered in combination with the full approved dose of paclitaxel.
Key facts
- Study ID
- NCT03057600
- Run by
- Calithera Biosciences, Inc
- People needed
- 52
- Starts
- 2017-05-01
- Expected to finish
- 2019-11-25
- Last updated by the study team
- 2022-09-28
Who can join
Age: 18 and older. Sex: female. Healthy volunteers: not accepted.
Where it is running
- University of Alabama at Brimingham — Birmingham, Alabama, United States
- University of South Alabama, Mitchell Cancer Institute — Mobile, Alabama, United States
- Yale Cancer Center — New Haven, Connecticut, United States
- Georgetown University - Lombardi Comprehensive Cancer Center — Washington D.C., District of Columbia, United States
- Washington Cancer Institute — Washington D.C., District of Columbia, United States
- University of Miami — Miami, Florida, United States
- Moffitt Cancer Center and Research Institute — Tampa, Florida, United States
- University Cancer and Blood Center — Athens, Georgia, United States
- Winship Cancer Institute - Emory University — Atlanta, Georgia, United States
- Northwest Georgia Oncology — Marietta, Georgia, United States
- Ochsner Clinic Foundation — New Orleans, Louisiana, United States
- Weinberg Cancer Institute at Franklin Square — Baltimore, Maryland, United States
- Henry Ford Hospital — Detroit, Michigan, United States
- Saint Louis University — St Louis, Missouri, United States
- JTCC at Hackensack UMC — Hackensack, New Jersey, United States
- Columbia University — New York, New York, United States
- University of Pennsylvania — Philadelphia, Pennsylvania, United States
- Magee Womens Hospital - UPMC — Pittsburgh, Pennsylvania, United States
- Charleston Hematology Oncology Associates — Charleston, South Carolina, United States
- Greenville Health System (GHS) Cancer Institute — Greenville, South Carolina, United States
- West Cancer Center — Germantown, Tennessee, United States
- Baylor College of Medicine — Houston, Texas, United States
- MD Anderson — Houston, Texas, United States
- Northwest Medical Specialties, PLLC — Tacoma, Washington, United States
- Froedtert and the Medical College of Wisconsin — Milwaukee, Wisconsin, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.